RESUMEN
Low-pass whole genome sequencing (LP-WGS) has been applied as alternative method to detect copy number variants (CNVs) in the clinical setting. Compared with chromosomal microarray analysis (CMA), the sequencing-based approach provides a similar resolution of CNV detection at a lower cost. In this study, we assessed the efficiency and reliability of LP-WGS as a more affordable alternative to CMA. A total of 1363 patients with unexplained neurodevelopmental delay/intellectual disability, autism spectrum disorders, and/or multiple congenital anomalies were enrolled. Those patients were referred from 15 nonprofit organizations and university centers located in different states in Brazil. The analysis of LP-WGS at 1x coverage (>50kb) revealed a positive testing result in 22% of the cases (304/1363), in which 219 and 85 correspond to pathogenic/likely pathogenic (P/LP) CNVs and variants of uncertain significance (VUS), respectively. The 16% (219/1363) diagnostic yield observed in our cohort is comparable to the 15%-20% reported for CMA in the literature. The use of commercial software, as demonstrated in this study, simplifies the implementation of the test in clinical settings. Particularly for countries like Brazil, where the cost of CMA presents a substantial barrier to most of the population, LP-WGS emerges as a cost-effective alternative for investigating copy number changes in cytogenetics.
Asunto(s)
Variaciones en el Número de Copia de ADN , Secuenciación Completa del Genoma , Humanos , Variaciones en el Número de Copia de ADN/genética , Secuenciación Completa del Genoma/economía , Secuenciación Completa del Genoma/métodos , Brasil , Masculino , Femenino , Niño , Discapacidad Intelectual/genética , Discapacidad Intelectual/diagnóstico , Análisis Costo-Beneficio , Análisis por Micromatrices/economía , Análisis por Micromatrices/métodos , Trastorno del Espectro Autista/genética , Trastorno del Espectro Autista/diagnóstico , Preescolar , Anomalías Múltiples/genética , Anomalías Múltiples/diagnóstico , Países en Desarrollo , Adolescente , Trastornos del Neurodesarrollo/genética , Trastornos del Neurodesarrollo/diagnóstico , Pruebas Genéticas/economía , Pruebas Genéticas/métodosRESUMEN
Mucopolysaccharidosis type IIIB (MPS IIIB) is caused by deficiency of alpha-N-acetylglucosaminidase, leading to storage of heparan sulphate. The disease is characterized by intellectual disability and hyperactivity, among other neurological and somatic features. Here we studied retrospective data from a total of 19 MPS IIIB patients from Brazil, aiming to evaluate disease progression. Mean age at diagnosis was 7.2 years. Speech delay was one of the first symptoms to be identified, around 2-3 years of age. Behavioral alterations include hyperactivity and aggressiveness, starting around age four. By the end of the first decade, patients lost acquired abilities such as speech and ability to walk. Furthermore, as disease progresses, respiratory, cardiovascular and joint abnormalities were found in more than 50% of the patients, along with organomegaly. Most common cause of death was respiratory problems. The disease progression was characterized in multiple systems, and hopefully these data will help the design of appropriate clinical trials and clinical management guidelines.